{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:04:43Z","timestamp":1753520683109,"version":"3.30.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11030-023-10766-9","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:02:19Z","timestamp":1701856939000},"page":"3363-3376","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rational design of FXR agonists: a computational approach for NASH therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Akshata","family":"Gandhe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masilamani","family":"Elizabeth Sobhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"3","key":"10766_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/gast.2001.27126","volume":"121","author":"AE Reid","year":"2001","unstructured":"Reid AE (2001) Nonalcoholic steatohepatitis. Gastroenterology 121(3):710\u2013723. https:\/\/doi.org\/10.1053\/gast.2001.27126","journal-title":"Gastroenterology"},{"issue":"6","key":"10766_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","volume":"7","author":"SM Abd El-Kader","year":"2015","unstructured":"Abd El-Kader SM, El-Den Ashmawy EMS (2015) Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 7(6):846. https:\/\/doi.org\/10.4254\/wjh.v7.i6.846","journal-title":"World J Hepatol"},{"issue":"8","key":"10766_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","volume":"65","author":"GT Brown","year":"2016","unstructured":"Brown GT, Kleiner DE (2016) Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metab 65(8):1080\u20131086. https:\/\/doi.org\/10.1016\/j.metabol.2015.11.008","journal-title":"Metab"},{"issue":"3","key":"10766_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","volume":"1","author":"M-M Balp","year":"2019","unstructured":"Balp M-M, Krieger N, Przybysz R, Way N, Cai J, Zappe D et al (2019) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study. JHEP Rep 1(3):154\u2013161. https:\/\/doi.org\/10.1016\/j.jhepr.2019.05.009","journal-title":"JHEP Rep"},{"issue":"1","key":"10766_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"3","key":"10766_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cld.1141","volume":"18","author":"A De","year":"2021","unstructured":"De A, Duseja A (2021) Nonalcoholic fatty liver disease: Indian perspective. Clin Liver Dis 18(3):158. https:\/\/doi.org\/10.1002\/cld.1141","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10766_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027244","volume":"9","author":"J Chalmers","year":"2019","unstructured":"Chalmers J, Ban L, Leena KB, Edwards KL, Grove JL, Aithal GP et al (2019) Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort. BMJ Open 9(5):e027244. https:\/\/doi.org\/10.1136\/bmjopen-2018-027244","journal-title":"BMJ Open"},{"issue":"5","key":"10766_CR8","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836\u20131846. https:\/\/doi.org\/10.1002\/hep.24001","journal-title":"Hepatology"},{"issue":"2","key":"10766_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4291\/wjgp.v7.i2.211","volume":"7","author":"S Alam","year":"2016","unstructured":"Alam S, Mustafa G, Alam M, Ahmad N (2016) Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 7(2):211. https:\/\/doi.org\/10.4291\/wjgp.v7.i2.211","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"8","key":"10766_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"issue":"4","key":"10766_CR11","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/nu12041082","volume":"12","author":"RM Chakaroun","year":"2020","unstructured":"Chakaroun RM, Massier L, Kovacs P (2020) Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? Nutrients 12(4):1082. https:\/\/doi.org\/10.3390\/nu12041082","journal-title":"Nutrients"},{"issue":"2","key":"10766_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3727\/105221617X15124844266408","volume":"18","author":"DJ Van der Windt","year":"2018","unstructured":"Van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H (2018) The effects of physical exercise on fatty liver disease. Gene Expr 18(2):89\u2013101. https:\/\/doi.org\/10.3727\/105221617X15124844266408","journal-title":"Gene Expr"},{"issue":"5","key":"10766_CR13","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/hep.31158","volume":"72","author":"D Kim","year":"2020","unstructured":"Kim D, Vazquez-Montesino LM, Li AA, Cholankeril G, Ahmed A (2020) Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 72(5):1556\u20131568. https:\/\/doi.org\/10.1002\/hep.31158","journal-title":"Hepatology"},{"key":"10766_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15738","author":"B Carlsson","year":"2020","unstructured":"Carlsson B, Lind\u00e9n D, Brol\u00e9n G, Liljeblad M, Bjursell M, Romeo S et al (2020) The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. https:\/\/doi.org\/10.1111\/apt.15738","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10766_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3727\/105221619X15536120524171","volume":"19","author":"M-M Chen","year":"2019","unstructured":"Chen M-M, Cai J-J, Yu Y, She Z-G, Li H (2019) Current and emerging approaches for nonalcoholic steatohepatitis treatment. Gene Expr 19(3):175\u2013185. https:\/\/doi.org\/10.3727\/105221619X15536120524171","journal-title":"Gene Expr"},{"issue":"10","key":"10766_CR16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JY Chiang","year":"2009","unstructured":"Chiang JY (2009) Bile acids: regulation of synthesis: thematic review series: bile acids. J Lipid Res 50(10):1955\u20131966. https:\/\/doi.org\/10.1194\/jlr.R900010-JLR200","journal-title":"J Lipid Res"},{"issue":"1","key":"10766_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","volume":"75","author":"C Kremoser","year":"2021","unstructured":"Kremoser C (2021) FXR agonists for NASH: How are they different and what difference do they make? J Hepatol 75(1):12\u201315","journal-title":"J Hepatol"},{"key":"10766_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbadis.2014.02.004","volume":"5","author":"C Kunne","year":"1842","unstructured":"Kunne C, Acco A, Duijst S, de Waart DR, Paulusma CC, Gaemers I et al (1842) (2014) FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model. Biochim Biophys Acta Mol Basis Dis 5:739\u2013746. https:\/\/doi.org\/10.1016\/j.bbadis.2014.02.004","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"9972","key":"10766_CR19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):956\u2013965. https:\/\/doi.org\/10.1016\/s0140-6736(14)61933-4","journal-title":"Lancet"},{"key":"10766_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105889","volume":"88","author":"M Pedrosa","year":"2020","unstructured":"Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M et al (2020) A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial. Contemp Clin Trials 88:105889. https:\/\/doi.org\/10.1016\/j.cct.2019.105889","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10766_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/apt.15967","volume":"52","author":"M Camilleri","year":"2020","unstructured":"Camilleri M, Nord SL, Burton D, Oduyebo I, Zhang Y, Chen J et al (2020) Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. Aliment Pharmacol Ther 52(5):808\u2013820. https:\/\/doi.org\/10.1111\/apt.15967","journal-title":"Aliment Pharmacol Ther"},{"key":"10766_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.bbrc.2020.10.039","volume":"534","author":"L Jiang","year":"2021","unstructured":"Jiang L, Xiao D, Li Y, Dai S, Qu L, Chen X et al (2021) Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. Biochem Biophys Res Commun 534:1047\u20131052. https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.039","journal-title":"Biochem Biophys Res Commun"},{"key":"10766_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","volume":"133","author":"S Traussnigg","year":"2021","unstructured":"Traussnigg S, Halilbasic E, Hofer H, Munda P, Stojakovic T, Fauler G et al (2021) Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wien Klin Wochenschr 133:441\u2013451. https:\/\/doi.org\/10.1007\/s00508-020-01735-5","journal-title":"Wien Klin Wochenschr"},{"key":"10766_CR24","first-page":"1267A","volume":"70","author":"P Radreau","year":"2019","unstructured":"Radreau P, Joly S, Dubos C, Vonderscher J, Scalfaro P, Meldrum E, Darteil R (2019) Vitro and in vivo characterization of Eyp001 a novel, potent and selective Fxr agonist now in a phase 2 clinical trial in Nash. Hepatology 70:1267A-1267A","journal-title":"Hepatology"},{"key":"10766_CR25","unstructured":"Scr\u00f6dinger Release S.2 (2021) Protein preparation wizard. Impact. Epik, Schr\u00f6dinger, New York"},{"issue":"5","key":"10766_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","volume":"67","author":"SL Dixon","year":"2006","unstructured":"Dixon SL, Smondyrev AM, Rao SN (2006) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67(5):370\u2013372. https:\/\/doi.org\/10.1111\/j.1747-0285.2006.00384.x","journal-title":"Chem Biol Drug Des"},{"issue":"10","key":"10766_CR27","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1021\/ci900212v","volume":"49","author":"NK Salam","year":"2009","unstructured":"Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49(10):2356\u20132368. https:\/\/doi.org\/10.1021\/ci900212v","journal-title":"J Chem Inf Model"},{"issue":"suppl_1","key":"10766_CR28","doi-asserted-by":"publisher","first-page":"D198","DOI":"10.1093\/nar\/gkl999","volume":"35","author":"T Liu","year":"2007","unstructured":"Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein\u2013ligand binding affinities. Nucleic Acids Res 35(suppl_1):D198\u2013D201. https:\/\/doi.org\/10.1093\/nar\/gkl999","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10766_CR29","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750\u20131759. https:\/\/doi.org\/10.1021\/jm030644s","journal-title":"J Med Chem"},{"issue":"D1","key":"10766_CR30","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"10766_CR31","doi-asserted-by":"publisher","first-page":"389364","DOI":"10.4061\/2011\/389364","volume":"2011","author":"LL Major","year":"2011","unstructured":"Major LL, Smith TK (2011) Screening the MayBridge rule of 3 fragment library for compounds that interact with the Trypanosoma brucei myo-inositol-3-phosphate synthase and\/or show trypanocidal activity. Mol Biol Int 2011:389364. https:\/\/doi.org\/10.4061\/2011\/389364","journal-title":"Mol Biol Int"},{"issue":"7019","key":"10766_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nature03197","volume":"432","author":"BK Shoichet","year":"2004","unstructured":"Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432(7019):862\u2013865. https:\/\/doi.org\/10.1038\/nature03197","journal-title":"Nature"},{"issue":"7","key":"10766_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"issue":"5","key":"10766_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"key":"10766_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0517.1000141","volume":"4","author":"N Chandna","year":"2015","unstructured":"Chandna N, Kumari K, Sharma C, Vijjulatha M, Kapoor J, Sharma P (2015) QM\/MM docking strategy and prime\/MM-GBSA calculation of celecoxib analogues as N-myristoyltransferase inhibitors. Virol Mycol 4:1\u20138. https:\/\/doi.org\/10.4172\/2161-0517.1000141","journal-title":"Virol Mycol"},{"issue":"16","key":"10766_CR36","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1021\/jm060522a","volume":"49","author":"PD Lyne","year":"2006","unstructured":"Lyne PD, Lamb ML, Saeh JC (2006) Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 49(16):4805\u20134808. https:\/\/doi.org\/10.1021\/jm060522a","journal-title":"J Med Chem"},{"issue":"16","key":"10766_CR37","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701\u20131718. https:\/\/doi.org\/10.1002\/jcc.20291","journal-title":"J Comput Chem"},{"issue":"11","key":"10766_CR38","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.20291","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32(11):2359\u20132368. https:\/\/doi.org\/10.1002\/jcc.20291","journal-title":"J Comput Chem"},{"key":"10766_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06605","author":"N Moussa","year":"2021","unstructured":"Moussa N, Hassan A, Gharaghani S (2021) Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e06605","journal-title":"Heliyon"},{"issue":"3","key":"10766_CR40","doi-asserted-by":"publisher","first-page":"e0119264","DOI":"10.1371\/journal.pone.0119264","volume":"10","author":"L Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez L (2015) Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PLoS ONE 10(3):e0119264. https:\/\/doi.org\/10.1371\/journal.pone.0119264","journal-title":"PLoS ONE"},{"key":"10766_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10570-021-04325-4","author":"M Wohlert","year":"2022","unstructured":"Wohlert M, Benselfelt T, W\u00e5gberg L, Fur\u00f3 I, Berglund LA, Wohlert J (2022) Cellulose and the role of hydrogen bonds: not in charge of everything. Cellulose. https:\/\/doi.org\/10.1007\/s10570-021-04325-4","journal-title":"Cellulose"},{"issue":"1","key":"10766_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5","journal-title":"J Mol Graph"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-023-10766-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:25:30Z","timestamp":1733149530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-023-10766-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10766"],"URL":"https:\/\/doi.org\/10.1007\/s11030-023-10766-9","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"type":"print","value":"1381-1991"},{"type":"electronic","value":"1573-501X"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"17 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}